This funding opportunity supports independent global healthcare initiatives including research, quality improvement, and education aimed at enhancing patient outcomes for infections caused by MBL-CRE or S. maltophilia. Projects should address unmet medical needs and align with Pfizer's medical and scientific strategies.
No eligibility criteria are provided for this funding opportunity.
